Skip to main
KRTX
KRTX logo

KRTX Stock Forecast & Price Target

KRTX Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 42%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Karuna Therapeutics is a clinical-stage biopharmaceutical company that has a positive outlook due to their promising product candidate, KarXT, which is an oral modulator of muscarinic receptors targeted towards disabling neuropsychiatric conditions. The company's pipeline efforts are progressing well, with multiple near-term catalysts expected, including Phase 3 data for KarXT and near-term data for ambulatory blood pressure monitoring. The company also maintains a strong financial position, with a cash runway through 2026 and a well-defined commercialization strategy. With a unique drug profile and limited competition in its target markets, Karuna Therapeutics has the potential to become a major player in the neuropsychiatric space.

Bears say

Karuna Therapeutics is a clinical-stage biotech company that is pursuing novel neuropsychiatric therapies, but their lack of focus on environmental, social, and governance (ESG) initiatives may not bode well for long-term sustainability. While the company has promising clinical data and a deep management team, they are still a speculative investment with no current revenue-generating products and face potential risks in development and commercialization, including COVID-19 related delays.

KRTX has been analyzed by 24 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Karuna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Karuna Therapeutics Inc (KRTX) Forecast

Analysts have given KRTX a Buy based on their latest research and market trends.

According to 24 analysts, KRTX has a Buy consensus rating as of Jul 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $265.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $265.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Karuna Therapeutics Inc (KRTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.